ZA201201229B - Methods of attenuating the loss of functional status - Google Patents

Methods of attenuating the loss of functional status

Info

Publication number
ZA201201229B
ZA201201229B ZA2012/01229A ZA201201229A ZA201201229B ZA 201201229 B ZA201201229 B ZA 201201229B ZA 2012/01229 A ZA2012/01229 A ZA 2012/01229A ZA 201201229 A ZA201201229 A ZA 201201229A ZA 201201229 B ZA201201229 B ZA 201201229B
Authority
ZA
South Africa
Prior art keywords
attenuating
loss
methods
functional status
status
Prior art date
Application number
ZA2012/01229A
Other languages
English (en)
Inventor
Kevin Burke Miller
Zamzam Kabiry Roughead
Ingo Arne Jurk
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of ZA201201229B publication Critical patent/ZA201201229B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
ZA2012/01229A 2009-07-20 2012-02-17 Methods of attenuating the loss of functional status ZA201201229B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22680609P 2009-07-20 2009-07-20
US33424710P 2010-05-13 2010-05-13
PCT/US2010/042083 WO2011011252A1 (en) 2009-07-20 2010-07-15 Methods of attenuating the loss of functional status

Publications (1)

Publication Number Publication Date
ZA201201229B true ZA201201229B (en) 2013-07-31

Family

ID=42990259

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/01229A ZA201201229B (en) 2009-07-20 2012-02-17 Methods of attenuating the loss of functional status

Country Status (13)

Country Link
US (1) US20120195873A1 (enExample)
EP (2) EP2456448A1 (enExample)
JP (1) JP2012533627A (enExample)
CN (1) CN102647990A (enExample)
AU (1) AU2010274125B2 (enExample)
BR (1) BR112012001488A2 (enExample)
CA (1) CA2768471A1 (enExample)
IN (1) IN2012DN00486A (enExample)
MX (1) MX2012000943A (enExample)
RU (1) RU2012105901A (enExample)
SG (1) SG177664A1 (enExample)
WO (1) WO2011011252A1 (enExample)
ZA (1) ZA201201229B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853148B2 (en) * 2010-03-12 2014-10-07 Nestec S.A. Compositions for masking the flavor of nutrients and methods for making same
CA2796936A1 (en) * 2010-04-26 2011-11-10 Nestec S.A. Nutritional compositions and methods for weaning from parenteral nutrition to enteral nutrition
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
EP2678010A1 (en) * 2011-02-25 2014-01-01 Merck Patent GmbH Composition to increase joint and/or postural stability
RU2013151090A (ru) * 2011-04-18 2015-05-27 Нестек С.А. Питательные композиции, содержащие альфа-гидроксиизокапроновую кислоту и эйкозапентаеновую кислоту
CA2836241A1 (en) * 2011-06-08 2012-12-13 Nestec S.A. Nutritional compositions having exogenous milk fat globule membrane components
JP2013051920A (ja) * 2011-09-05 2013-03-21 Ishikawa Prefectural Public Univ Corp 骨密度強化補助食品
EP2580967A1 (en) * 2011-10-11 2013-04-17 Nestec S.A. Accelerating muscle recovery after immobilization-induced muscle atrophy
EP2583565A1 (en) * 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for enhancing energy expenditure and satiety
EP2583563A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
EP2583566B1 (en) * 2011-10-21 2015-08-19 Nestec S.A. Whey protein micelles to enhance muscle mass and performance
EP2800478A2 (en) * 2012-01-03 2014-11-12 Nestec S.A. Compositions and methods for the stability of reactive amino acids in a food matrix
RU2520036C2 (ru) * 2012-03-01 2014-06-20 Общество с ограниченной ответственностью "Институт новых технологий" Пищевой продукт "миоактив-спорт" для питания людей, подверженных интенсивным физическим нагрузкам
US9579347B2 (en) * 2012-10-04 2017-02-28 Abbott Laboratories Methods for enhancing the effect of EGCg on mitigating skeletal muscle loss
CN103783532B (zh) * 2012-10-29 2016-06-08 杭州纽曲星生物科技有限公司 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法
CN103271350B (zh) * 2013-03-04 2014-09-24 中国航天员科研训练中心 空间站航天员太空高能压缩食品及其制法
CN105188695A (zh) 2013-03-14 2015-12-23 雅培制药有限公司 与长期体力活动不足有关的胰岛素抗性的治疗
CA2903565A1 (en) 2013-03-15 2014-09-18 Abbott Laboratories Methods of maintaining and improving muscle function using epigallocatechin-3-gallate
US20160051814A1 (en) * 2013-04-15 2016-02-25 Nestec S.A. Use of whey protein in combination with electrical muscle stimulation
HK1221609A1 (zh) * 2013-05-01 2017-06-09 Abbott Laboratories 增强老化肌肉再生的方法
US20140357576A1 (en) * 2013-05-31 2014-12-04 Nestec S.A. Methods for enhancement of muscle protein synthesis
WO2014200332A1 (en) 2013-06-10 2014-12-18 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
JP6279851B2 (ja) * 2013-07-19 2018-02-14 雪印メグミルク株式会社 筋萎縮防止及び／又は筋合成促進剤
AU2015294059B2 (en) 2014-07-21 2019-03-14 Société des Produits Nestlé S.A. Nutritional products to promote safe swallowing for individuals with dysphagia
ES2651903T3 (es) * 2014-10-08 2018-01-30 Professional Dietetics S.P.A. Composiciones que comprenden aminoácidos para su uso en el tratamiento del estado inflamatorio sistémico asociado con el accidente cerebrovascular en pacientes con disfagia
JP6826033B2 (ja) * 2014-10-14 2021-02-03 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 高齢男性の筋機能の改善
ES2727660T3 (es) * 2014-11-19 2019-10-17 Nestle Sa Uso de complejos de micelas de proteína de suero y pectina para controlar el peso corporal
EP3377077A1 (en) * 2015-11-20 2018-09-26 Nestec S.A. Methods using whey protein to improve or maintain muscle quality
JP7300243B2 (ja) * 2015-12-03 2023-06-29 株式会社明治 栄養組成物
JP6935403B2 (ja) 2015-12-22 2021-09-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー サルコペニア及びフレイルの処置方法
JP6848962B2 (ja) * 2016-03-16 2021-03-24 味の素株式会社 行動体力向上剤
JP2019513802A (ja) * 2016-04-14 2019-05-30 ルシー マイケル 組み合わせ組成物およびその使用方法
JP6948103B2 (ja) * 2016-04-14 2021-10-13 株式会社明治 フレイル改善用組み合わせ物
AU2017270131B2 (en) * 2016-05-27 2023-03-09 Société des Produits Nestlé S.A. Nutritional composition for treating or preventing impaired mobility
WO2018091564A1 (en) * 2016-11-16 2018-05-24 Fresenius Kabi Deutschland Gmbh Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018157258A1 (en) 2017-03-03 2018-09-07 Exerkine Corporation Multi-nutrient composition
WO2018221526A1 (ja) * 2017-06-01 2018-12-06 株式会社明治 栄養組成物
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法
JP7044306B2 (ja) * 2018-07-31 2022-03-30 ユーハ味覚糖株式会社 ロイシン血中濃度上昇促進剤及びその用途
CA3122323A1 (en) * 2018-12-13 2020-06-18 Societe Des Produits Nestle S.A. Liquid concentrates formulated for dilution into nutritional products to promote safe swallowing for individuals with dysphagia
WO2020260689A1 (en) * 2019-06-28 2020-12-30 Dompe' Farmaceutici Spa New composition containing branched-chain amino acids
EP4049672A4 (en) * 2019-10-25 2023-11-29 Ajinomoto Co., Inc. Muscle quality improvement agent

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2683492B2 (ja) * 1993-09-07 1997-11-26 雪印乳業株式会社 ミセル状ホエー蛋白質、その溶液、その粉末およびミセル状ホエー蛋白質の製造法
CN1101810A (zh) * 1994-08-23 1995-04-26 谢宝兴 茯苓枸杞子口服液饮料袋泡茶及其生产方法
EP1062876A1 (en) * 1999-02-25 2000-12-27 Societe Des Produits Nestle S.A. Caseinoglycomacropeptides as calcification agent
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
US7794770B2 (en) * 2004-10-07 2010-09-14 Next Proteins, Inc. Protein beverage and method of making the same
CA2537647A1 (en) * 2005-03-01 2006-09-01 Six Star Formulations Ltd. Supplemental dietary composition for supporting muscle growth, recovery and strength
FR2882896B1 (fr) * 2005-03-14 2007-05-04 Larena Sa Composition alimentaire pour prevenir le syndrome de fragilite chez les personnes agees
US20070020358A1 (en) * 2005-03-18 2007-01-25 Mower Thomas E Sports drink concentrate
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
WO2007028211A1 (en) * 2005-09-09 2007-03-15 Murray Goulburn Co-Operative Co Limited Composition of whey growth factor extract for reducing muscle inflammation
ES2359255T3 (es) * 2006-03-27 2011-05-19 Nestec S.A. Postre congelado enriquecido con proteínas.
PT1839504E (pt) * 2006-03-27 2009-05-11 Nestec Sa Preparação in situ de micelas de proteína de soro de leite
CA2666871C (en) * 2006-10-19 2011-08-30 Nestec S.A. Long term feed - cancer patient
AR060847A1 (es) 2007-05-03 2008-07-16 Spannagel Lucia Antonia Formulacion a base de calendula, aloe y centella.
WO2009143097A1 (en) * 2008-05-21 2009-11-26 Stokely-Van Camp, Inc. Milk-based recovery beverage
WO2010002242A1 (en) * 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity

Also Published As

Publication number Publication date
US20120195873A1 (en) 2012-08-02
AU2010274125A1 (en) 2012-02-16
JP2012533627A (ja) 2012-12-27
AU2010274125B2 (en) 2015-11-05
RU2012105901A (ru) 2013-08-27
CA2768471A1 (en) 2011-01-27
EP2456448A1 (en) 2012-05-30
CN102647990A (zh) 2012-08-22
IN2012DN00486A (enExample) 2015-05-22
WO2011011252A1 (en) 2011-01-27
EP3231435A1 (en) 2017-10-18
MX2012000943A (es) 2012-02-28
BR112012001488A2 (pt) 2019-10-08
SG177664A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
ZA201201229B (en) Methods of attenuating the loss of functional status
IL219133A0 (en) Antimicrobial compounds and methods of making and using the same
GB201020387D0 (en) Unterbaustruktur einer kraftfahrzeugkarosserie
EP2432847A4 (en) MODIFYING INTERFACES OF HYDROCARBON-FINISHED SURFACES
IL219135A0 (en) Antimicrobial compounds and methods of making and using the same
AU330863S (en) Earplug
PL2391257T3 (pl) Zmywarka mająca struktury tłumiące dźwięk
IL257837A (en) Antimicrobial compounds and methods for their preparation and use
GB0905818D0 (en) Coupling assembly
GB0919555D0 (en) Closable throughflow member
GB0922610D0 (en) Earphone
PL2387446T3 (pl) Kombinacyjny filtr
SG10201406635QA (en) Antimicrobial compounds and methods of making and using the same
ZA201000148B (en) Filter assembly
GB0919485D0 (en) Filter assembly
GB0913961D0 (en) Filter assembly
GB0911008D0 (en) Coupling Assembly
GB0914823D0 (en) The feedifier
GB0903999D0 (en) Aircraft acoustic attenuation
GB0906819D0 (en) Geoengineering structures
GB2472309B (en) Acoustic curtain
GB0916506D0 (en) Structures
HK1168301A (en) Methods of attenuating the loss of functional status
AU4046P (en) Tarwan Urochloa mosambicensis
GB0915478D0 (en) Acoustic transmission